Shukra Pharma.

{
  "main_header": {
    "sid": 505931,
    "name": "Shukra Pharma.",
    "stock_name": "Shukra Pharma.",
    "full_name": "Shukra Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/shukra-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "29.97",
    "chg": 0.81,
    "chgp": "2.78%",
    "dir": 1,
    "prev_price": "29.16",
    "mcapval": "1,319.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524632,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE551C01044",
    "curr_date": "Jun 12, 03:30 PM",
    "curr_time": "10:48 AM",
    "last_traded_at": "Jun 12, 03:30 PM IST",
    "bse_nse_vol": "1.38 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 12, 2026",
    "traded_date_str": "2026 06 12",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/shukra-pharma-505931-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Shukra Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/shukra-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-4043261",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ShukraPharmaceu_technicaldot_4043261.png",
        "date": "2026-06-10 08:02:49",
        "description": "Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price retreating 3.42% on 10 June 2026 to close at ₹30.78, down from the previous close of ₹31.87."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/shukra-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4040011",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ShukraPharmaceu_technicaldot_4040011.png",
        "date": "2026-06-09 08:00:45",
        "description": "Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a modest daily price increase of 1.30%, the stock’s technical indicators reveal a nuanced momentum change, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-sell-4037679",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ShukraPharmaceu_mojoScore_4037679.png",
        "date": "2026-06-06 10:10:19",
        "description": "Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-sell-4037785",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/ShukraPharmaceu_mojoScore_4037785.png",
        "date": "2026-06-05 10:10:05",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-sell-4010335",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ShukraPharmaceu_mojoScore_4010335.png",
        "date": "2026-05-25 10:10:03",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/shukra-pharmaceuticals-ltd-is-rated-sell-3991114",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ShukraPharmaceu_mojoScore_3991114.png",
        "date": "2026-05-14 10:10:03",
        "description": "Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Shukra Pharmaceuticals Gains 9.97%: Mixed Signals Shape Weekly Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/shukra-pharmaceuticals-gains-997-mixed-signals-shape-weekly-performance-3983611",
        "imagepath": "",
        "date": "2026-05-09 17:06:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>May 4:</strong> Bearish technical shift noted amid mixed momentum signals</p>\n                    <p><strong>May 5-7:</strong> Consecutive strong price gains with rising volumes</p>\n                    <p><strong>May 8:</strong> Mixed quarterly results reported, stock closes lower</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.30.50</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.33.54</div><div class=\"stat-change positive\">+9.97%</div></div>\n                    <div class=\"stat-i..."
      },
      {
        "title": "Are Shukra Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-shukra-pharmaceuticals-ltd-latest-results-good-or-bad-3982331",
        "imagepath": "",
        "date": "2026-05-08 19:18:18",
        "description": "Shukra Pharmaceuticals Ltd's latest financial results for the quarter ending March 2026 reveal significant operational challenges. The company's net sales experienced a dramatic decline of approximately 83.85% quarter-on-quarter, dropping to ₹6.32 crores from ₹39.13 crores in the previous quarter. This steep fall raises concerns about revenue recognition practices and suggests potential volatility in the company's operational performance.\n\nIn terms of profitability, Shukra Pharmaceuticals reported a net loss of ₹1.72 crores for the quarter, which reflects a substantial decline compared to the previous quarter's profit. The operating margin also contracted sharply to 11.08%, down from an exceptionally high 69.33% in the prior quarter. This compression in margins indicates a significant shift in the company's cost structure or product mix, which may have been influenced by pricing pressures or changes in dema..."
      },
      {
        "title": "Shukra Pharmaceuticals Q4 FY26: Sharp Quarterly Decline Masks Six-Month Strength",
        "link": "https://www.marketsmojo.com/news/result-analysis/shukra-pharmaceuticals-q4-fy26-sharp-quarterly-decline-masks-six-month-strength-3981987",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ShukraPharmaceu_quaterlyResult_3981987.png",
        "date": "2026-05-08 14:46:38",
        "description": "Shukra Pharmaceuticals Ltd. reported a challenging fourth quarter for FY26, with net profit swinging to a loss of ₹1.72 crores from a profit of ₹5.39 crores in the same period last year, marking a sharp 154.43% year-on-year decline. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,469 crores, saw its stock decline 4.99% to ₹33.54 following the results announcement, as investors reacted to the dramatic quarterly reversal despite strong half-yearly performance."
      }
    ],
    "total": 642,
    "sid": "505931",
    "stock_news_url": "https://www.marketsmojo.com/news/shukra-pharmaceuticals-505931"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Wednesday June 10 2026",
      "datetime": "10-Jun-2026",
      "details": "Outcome of the meeting of the Board of Directors held on Wednesday June 10 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Ratification Of Approval For Members Resolution Passed In The Extra-Ordinary General Meeting Dated 01St November 2025",
      "datetime": "05-Jun-2026",
      "details": "Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/06/2026 inter alia to consider and approve Ratification of Approval for members resolution passed in the Extra-Ordinary General Meeting dated 01st November 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "09-May-2026",
      "details": "Newspaper publication of Standalone Audit Financial Results for Fourth Quarter and Financial Year ended on 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has declared <strong>1%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>1:10</strong> stock split, ex-date: 21 Mar 25",
          "dt": "2025-03-21",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 19 Apr 24",
          "dt": "2024-04-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Shukra Pharmaceuticals Ltd has announced <strong>6:1</strong> rights issue, ex-date: 02 Feb 23",
          "dt": "2023-02-02",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Shukra Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-06-10 08:02:49

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price retreating 3.42% on 10 June 2026 to close at ₹30.78, down from the previous close of ₹31.87.

Read full news article

Shukra Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-06-09 08:00:45

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a modest daily price increase of 1.30%, the stock’s technical indicators reveal a nuanced momentum change, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Sell

2026-06-06 10:10:19

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Sell

2026-06-05 10:10:05

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Sell

2026-05-25 10:10:03

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Shukra Pharmaceuticals Ltd is Rated Sell

2026-05-14 10:10:03

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Shukra Pharmaceuticals Gains 9.97%: Mixed Signals Shape Weekly Performance

2026-05-09 17:06:37

Key Events This Week

May 4: Bearish technical shift noted amid mixed momentum signals

May 5-7: Consecutive strong price gains with rising volumes

May 8: Mixed quarterly results reported, stock closes lower

Week Open

Rs.30.50

Week Close

Rs.33.54

+9.97%

Read full news article

Are Shukra Pharmaceuticals Ltd latest results good or bad?

2026-05-08 19:18:18

Shukra Pharmaceuticals Ltd's latest financial results for the quarter ending March 2026 reveal significant operational challenges. The company's net sales experienced a dramatic decline of approximately 83.85% quarter-on-quarter, dropping to ₹6.32 crores from ₹39.13 crores in the previous quarter. This steep fall raises concerns about revenue recognition practices and suggests potential volatility in the company's operational performance. In terms of profitability, Shukra Pharmaceuticals reported a net loss of ₹1.72 crores for the quarter, which reflects a substantial decline compared to the previous quarter's profit. The operating margin also contracted sharply to 11.08%, down from an exceptionally high 69.33% in the prior quarter. This compression in margins indicates a significant shift in the company's cost structure or product mix, which may have been influenced by pricing pressures or changes in dema...

Read full news article

Shukra Pharmaceuticals Q4 FY26: Sharp Quarterly Decline Masks Six-Month Strength

2026-05-08 14:46:38

Shukra Pharmaceuticals Ltd. reported a challenging fourth quarter for FY26, with net profit swinging to a loss of ₹1.72 crores from a profit of ₹5.39 crores in the same period last year, marking a sharp 154.43% year-on-year decline. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,469 crores, saw its stock decline 4.99% to ₹33.54 following the results announcement, as investors reacted to the dramatic quarterly reversal despite strong half-yearly performance.

Read full news article

View All News